IGC Pharma, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that IGC Pharma, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.27M | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | $1.35M | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | $911.0K | Jun 24, 2024 |
| FY2023 | Mar 31, 2022 | $397.0K | Jul 7, 2023 |
| FY2022 | Mar 31, 2021 | $898.0K | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | $4.07M | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | $5.12M | Jul 13, 2020 |
| FY2019 | Mar 31, 2018 | $2.19M | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | $580.4K | Jun 21, 2018 |
| FY2017 | Mar 31, 2016 | $6.37M | Jul 14, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $619.0K | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | $733.0K | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | $442.0K | Jun 24, 2024 |
| FY2023 | Mar 31, 2022 | $194.0K | Jul 7, 2023 |
| FY2022 | Mar 31, 2021 | $113.0K | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | $115.0K | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | $132.0K | Jul 13, 2020 |
| FY2019 | Mar 31, 2018 | $82.0K | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | $218.2K | Jun 21, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($7.12M) | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | ($13.00M) | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | ($11.51M) | Jun 24, 2024 |
| FY2023 | Mar 31, 2022 | ($15.02M) | Jul 7, 2023 |
| FY2022 | Mar 31, 2021 | ($8.81M) | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | ($7.32M) | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | ($4.10M) | Jul 13, 2020 |
| FY2019 | Mar 31, 2018 | ($1.79M) | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | ($1.87M) | Jun 21, 2018 |
| FY2017 | Mar 31, 2016 | ($2.81M) | Jul 14, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($7.45M) | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | ($9.80M) | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | ($11.57M) | Jun 24, 2024 |
| FY2023 | Mar 31, 2022 | ($15.43M) | Jul 7, 2023 |
| FY2022 | Mar 31, 2021 | ($8.72M) | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | ($6.86M) | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | ($4.64M) | Jul 13, 2020 |
| FY2019 | Mar 31, 2018 | ($1.79M) | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | ($2.05M) | Jun 21, 2018 |
| FY2017 | Mar 31, 2016 | ($2.91M) | Jul 14, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $3.66M | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | $3.77M | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | $3.46M | Jun 24, 2024 |
| FY2023 | Mar 31, 2022 | $2.33M | Jul 7, 2023 |
| FY2022 | Mar 31, 2021 | $929.0K | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | $1.01M | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | $1.26M | Jul 13, 2020 |
| FY2019 | Mar 31, 2018 | $137.0K | Jun 14, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $4.41M | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | $6.76M | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | $8.55M | Jun 24, 2024 |
| FY2023 | Mar 31, 2022 | $13.29M | Jul 7, 2023 |
| FY2022 | Mar 31, 2021 | $7.91M | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | $5.97M | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | $3.52M | Jul 13, 2020 |
| FY2019 | Mar 31, 2018 | $1.73M | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | $2.27M | Jun 21, 2018 |
| FY2017 | Mar 31, 2016 | $2.70M | Jul 14, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($4.80M) | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | ($5.20M) | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | ($7.05M) | Jun 24, 2024 |
| FY2023 | Mar 31, 2022 | ($7.46M) | Jul 7, 2023 |
| FY2022 | Mar 31, 2021 | ($10.80M) | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | ($8.68M) | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | ($3.33M) | Jul 13, 2020 |
| FY2019 | Mar 31, 2018 | ($1.93M) | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | ($1.39M) | Jun 21, 2018 |
| FY2017 | Mar 31, 2016 | ($157.7K) | Jul 14, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $112.0K | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | $138.0K | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | $310.0K | Jun 24, 2024 |
| FY2023 | Mar 31, 2022 | $236.0K | Jul 7, 2023 |
| FY2022 | Mar 31, 2021 | $1.47M | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | $4.39M | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | $15.0K | Jul 13, 2020 |
| FY2019 | Mar 31, 2018 | $136.0K | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | $145.7K | Jun 21, 2018 |
| FY2017 | Mar 31, 2016 | $122.2K | Jul 14, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $8.75M | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | $9.90M | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | $17.18M | Jun 24, 2024 |
| FY2023 | Mar 31, 2022 | $26.83M | Jul 7, 2023 |
| FY2022 | Mar 31, 2021 | $35.87M | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | $28.98M | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | $34.47M | Jul 13, 2020 |
| FY2019 | Mar 31, 2018 | $10.85M | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | $11.28M | Jun 21, 2018 |
| FY2017 | Mar 31, 2016 | $18.86M | Jul 14, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $2.42M | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | $2.58M | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | $2.27M | Jun 24, 2024 |
| FY2023 | Mar 31, 2022 | $2.94M | Jul 7, 2023 |
| FY2022 | Mar 31, 2021 | $3.06M | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | $2.45M | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | $893.0K | Jul 13, 2020 |
| FY2019 | Mar 31, 2018 | $2.79M | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | $3.93M | Jun 21, 2018 |
| FY2017 | Mar 31, 2016 | $4.91M | Jul 14, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $6.33M | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | $7.32M | Jun 27, 2025 |
| FY2025 | Mar 31, 2023 | $14.91M | Jun 27, 2025 |
| FY2024 | Mar 31, 2022 | $23.89M | Jun 24, 2024 |
| FY2023 | Mar 31, 2021 | $32.80M | Jul 7, 2023 |
| FY2022 | Mar 31, 2020 | $26.54M | Jun 23, 2022 |
| FY2018 | Mar 31, 2018 | $8.06M | Jun 21, 2018 |
| FY2018 | Mar 31, 2017 | $7.36M | Jun 21, 2018 |
| FY2017 | Mar 31, 2016 | $13.48M | Jul 14, 2017 |
| FY2016 | Mar 31, 2015 | $14.23M | Jul 14, 2016 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Mar 31, 2018 | $0 | Jun 21, 2018 |
| FY2018 | Mar 31, 2017 | $198.2K | Jun 21, 2018 |
| FY2017 | Mar 31, 2016 | $1.18M | Jul 14, 2017 |
| FY2016 | Mar 31, 2015 | $982.8K | Jul 14, 2016 |
| FY2015 | Mar 31, 2014 | $0 | Jul 14, 2015 |
| FY2013 | Mar 31, 2013 | $0 | Jul 15, 2014 |
| FY2013 | Mar 31, 2012 | $965.7K | Jul 15, 2014 |
| FY2011 | Mar 31, 2011 | $410.5K | Jul 16, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($120.74M) | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | ($113.67M) | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | ($100.67M) | Jun 24, 2024 |
| FY2023 | Mar 31, 2022 | ($89.16M) | Jul 7, 2023 |
| FY2022 | Mar 31, 2021 | ($74.14M) | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | ($65.37M) | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | ($58.05M) | Jul 13, 2020 |
| FY2019 | Mar 31, 2018 | ($53.80M) | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | ($52.01M) | Jun 21, 2018 |
| FY2017 | Mar 31, 2016 | ($50.14M) | Jul 14, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $405.0K | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | $1.20M | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | $3.20M | Jun 24, 2024 |
| FY2023 | Mar 31, 2022 | $10.46M | Jul 7, 2023 |
| FY2022 | Mar 31, 2021 | $14.55M | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | $7.26M | Jun 14, 2021 |
| FY2021 | Mar 31, 2019 | $25.61M | Jun 14, 2021 |
| FY2020 | Mar 31, 2018 | $1.66M | Jul 13, 2020 |
| FY2019 | Mar 31, 2017 | $538.0K | Jun 14, 2019 |
| FY2018 | Mar 31, 2016 | $1.49M | Jun 21, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jun 27, 2025 |
| FY2017 | Mar 31, 2017 | 0 | Jul 14, 2017 |
| FY2017 | Mar 31, 2016 | 0 | Jul 14, 2017 |
| FY2016 | Mar 31, 2015 | 0 | Jul 14, 2016 |
| FY2015 | Mar 31, 2014 | 0 | Jul 14, 2015 |
| FY2014 | Mar 31, 2013 | 0 | Jul 15, 2014 |
| FY2013 | Mar 31, 2012 | (2) | Jul 15, 2014 |
| FY2011 | Mar 31, 2011 | (1) | Jul 16, 2012 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jun 27, 2025 |
| FY2017 | Mar 31, 2017 | 0 | Jul 14, 2017 |
| FY2017 | Mar 31, 2016 | 0 | Jul 14, 2017 |
| FY2016 | Mar 31, 2015 | 0 | Jul 14, 2016 |
| FY2015 | Mar 31, 2014 | 0 | Jul 14, 2015 |
| FY2014 | Mar 31, 2013 | 0 | Jul 15, 2014 |
| FY2013 | Mar 31, 2012 | (2) | Jul 15, 2014 |
| FY2011 | Mar 31, 2011 | (1) | Jul 16, 2012 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 80.88M | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | 66.69M | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | 53.08M | Jun 24, 2024 |
| FY2023 | Mar 31, 2022 | 51.05M | Jul 7, 2023 |
| FY2022 | Mar 31, 2021 | 47.83M | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | 39.32M | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | 39.50M | Jul 13, 2020 |
| FY2019 | Mar 31, 2018 | 30.76M | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | 28.27M | Jun 21, 2018 |
| FY2017 | Mar 31, 2016 | 23.27M | Jul 14, 2017 |